Longhorn Vaccines and Diagnostics, a One Health company focused on global public health and zoonosis concerns, will be presenting new data at the 17th Vaccine Congress in Glasgow, Scotland. The study examined the effectiveness of LHNVD-201, an unconjugated peptide vaccine, in mitigating co-infections with influenza and SARS-CoV-2 (Covid-19).
The research conducted by Longhorn Vaccines and Diagnostics aimed to assess the durability and broad strain coverage of the LHNVD-201 vaccine. The results of the animal study showed promising outcomes, indicating that the vaccine could potentially provide long-term protection against both influenza and Covid-19 co-infections.
By developing a peptide-based vaccine, Longhorn Vaccines and Diagnostics aimed to address the challenges of rapidly evolving strains of influenza and SARS-CoV-2. Unlike traditional vaccines, which often target specific strains, LHNVD-201 focuses on the conserved regions of the viruses, increasing its potential for broad strain coverage.
The 17th Vaccine Congress, where the findings will be presented, offers an opportunity for scientists, researchers, and industry experts to share their insights and advancements in vaccine development. The in-person conference will provide a platform for networking and collaboration in the field of immunization.
Longhorn Vaccines and Diagnostics’ research on the LHNVD-201 vaccine contributes to the ongoing efforts to combat the global health challenges posed by influenza and Covid-19. The study’s findings add to the growing body of evidence supporting the development of peptide-based vaccines as a potential solution to rapidly evolving and co-infectious viruses.
In conclusion, the upcoming presentation at the 17th Vaccine Congress by Longhorn Vaccines and Diagnostics will highlight the durability and broad strain coverage of the LHNVD-201 vaccine. This research brings us one step closer to developing effective vaccines that can provide long-term protection against influenza and Covid-19 co-infections.
Sources:
– Longhorn Vaccines and Diagnostics (internal data)
